Moleculin Stock Insiders

MBRX
 Stock
  

USD 1.70  0.01  0.58%   

Break down of Moleculin Biotech management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Moleculin Biotech future performance.
Additionally, see Stocks Correlation.

Moleculin Biotech Return on Sales

(8.35)

Symbol  MBRX
Name  Moleculin Biotech CS
TypeStock
Country   United States
Exchange  NASDAQ

Information on Moleculin Biotech CS Leadership is currently not available.

If you believe this information is not accurate please let us know and we will check it out.

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Moleculin Biotech Management Team Effectiveness

Moleculin Biotech has return on total asset (ROA) of (16.77) % which means that it has lost $16.77 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (22.73) %, meaning that it created substantial loss on money invested by shareholders. Moleculin Biotech management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Invested Capital is likely to rise to 12.52 in 2022, whereas Return on Average Assets are likely to drop (0.19)  in 2022. Moleculin Biotech Total Assets are fairly stable at the moment as compared to the past year. Moleculin Biotech reported Total Assets of 84.09 Million in 2021. Current Assets is likely to rise to about 78.2 M in 2022, whereas Goodwill and Intangible Assets are likely to drop slightly above 10 M in 2022.

Moleculin Biotech Quarterly Total Assets

78.8 Million

Weighted Average Shares is likely to rise to about 29 M in 2022. Weighted Average Shares Diluted is likely to rise to about 29 M in 2022

Moleculin Biotech Workforce Comparison

Moleculin Biotech CS is regarded second in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 10,505. Moleculin Biotech adds roughly 13.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.

Moleculin Biotech Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moleculin Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moleculin Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Moleculin Biotech insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Moleculin Biotech Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Moleculin Biotech Price Series Summation is a cross summation of Moleculin Biotech price series and its benchmark/peer.
.

About Moleculin Biotech Management Performance

The success or failure of an entity such as Moleculin Biotech often depends on how effective the management is. Moleculin Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Moleculin management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Moleculin management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Return on Average Assets(0.17) (0.19) 
Return on Average Equity(0.19) (0.21) 
Return on Invested Capital 12.21  12.52 
Return on Sales(7.74) (8.35) 
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.
The data published in Moleculin Biotech's official financial statements usually reflect Moleculin Biotech's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Moleculin Biotech. For example, before you start analyzing numbers published by Moleculin accountants, it's critical to develop an understanding of what Moleculin Biotech's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Moleculin Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moleculin Biotech's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Moleculin Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Moleculin Biotech CS. Please utilize our Beneish M Score to check the likelihood of Moleculin Biotech's management to manipulate its earnings.
Additionally, see Stocks Correlation. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
48.6 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.